14 May 2020 --- Gencor’s palmitoylethanolamide (PEA) ingredient, called Levagen+, has demonstrated almost double absorption potential when administered via Pharmako Biotechnologies’ Lipisperse dispersion technology. This is according to a new, Gencor-endorsed pharmacokinetic study published in the Journal of Nutraceuticals and Food Science. Regulatory confusion over cannabinoids (CBD) is freeing up the space for alternatives, within which Gencor’s PEA ingredient fits, according to the company. The ingredient is touted as having anti-inflammatory and pain relief properties.
